Protein engineering market predicted to be worth $3.9 billion by 2024
A report on the protein engineering market suggests it will grow at a CAGR of 12.4 percent, primarily due to protein-based drugs and pharmaceutical company development.
List view / Grid view
A report on the protein engineering market suggests it will grow at a CAGR of 12.4 percent, primarily due to protein-based drugs and pharmaceutical company development.
The US FDA has revealed its action plan to aid in the development and advancement of diagnostics and medical countermeasures to combat the novel coronavirus 2019.
Researchers predict that the market for mass spectrometers will be worth $1.9 billion by 2025 due to demand for faster and more accurate technology.
The US FDA approved Tepezza (teprotumumab-trbw), the first treatment for thyroid eye, on the basis of two trials in which the drug improved eye protrusion in patients.
The CMA has announced Tiofarma admits taking part in an anti-competitive agreement with Amilco and Aspen which resulted in huge price increase in fludrocortisone acetate tablets.
China has started to regularly update its National Reimbursement Drug List (NRDL) which could lead to new opportunities for innovative drug manufacturers to foray into the Chinese market, say researchers.
The ABPI has announced that the pharmaceutical industry will give the NHS Scotland £70 million, or £1 million a week, to fund new medicines.
Following 250 US drug price increases in 2020 already, this article explores why costs are rising, what changes could ensure brand reputations remain intact and what manufacturers can do to ensure they get their share.
A new report has shown a high level of novelty and diversity for the HIV first-in-class pipeline which targets drug resistance and latency reversal.
Inflazome has announced that the US and EU will grant patents to their NLRP3 inflammasome inhibiting compounds.
New research has found that the cell and gene therapy clinical environment in the UK has encouraged commercial sponsorship from around the world.
The report reveals practical regulatory reforms that could move the globe closer to the UN’s goal of achieving universal health coverage by 2030.
A study suggests the global neoantigen cancer vaccine market will grow exponentially due to expected drug launches, new technology reducing costs and currently unmet needs of the market.
The NICE committee has made palbociclib with fulvestrant available on the Cancer Drug Fund for patients with hormone receptor-positive, HER2-negative, advanced breast cancer.
The pharmaceutical packaging equipment market is expected to reach a value of $11.46 billion due to market leader innovations and tightening packaging regulations, says report.